KPIs & Operating Metrics(New)
Breakdown Of AssetsCost Of RevenueDiaggregated Revenue AnnualDiaggregated Revenue Mix Annual %Disaggregated RevenueDisaggregated Revenue Mix %Employee StatisticsIncome Before Provisions For Income TaxesNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNon Gaap Profitability Annual %Opex As A % Of RevenueOPEX BreakdownProfitability AnnualProperty And Equipment, NetRevenueRevenue AnnualRevenue From PayorsRevenue From Payors AnnualRevenue Mix From Payors %Revenue Mix From Payors Annual %Test Reports DeliveredTest Reports Delivered BreakdownTest Reports Delivered Total
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Castle Biosciences (CSTL) Cost Of Revenue (2018 - 2025)

Castle Biosciences' Cost of Revenue history spans 8 years, with the latest figure at $18.3 million for Q4 2025.

  • On a quarterly basis, Cost of Revenue rose 13.17% to $18.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $71.0 million, a 17.98% increase, with the full-year FY2025 number at $71.0 million, up 17.98% from a year prior.
  • Cost of Revenue hit $18.3 million in Q4 2025 for Castle Biosciences, down from $18.7 million in the prior quarter.
  • Over the last five years, Cost of Revenue for CSTL hit a ceiling of $18.7 million in Q3 2025 and a floor of $3.0 million in Q1 2021.
  • Historically, Cost of Revenue has averaged $11.2 million across 5 years, with a median of $11.2 million in 2023.
  • Biggest five-year swings in Cost of Revenue: plummeted 52.53% in 2021 and later skyrocketed 107.9% in 2022.
  • Tracing CSTL's Cost of Revenue over 5 years: stood at $4.6 million in 2021, then surged by 107.09% to $9.5 million in 2022, then soared by 30.49% to $12.4 million in 2023, then surged by 30.27% to $16.2 million in 2024, then increased by 13.17% to $18.3 million in 2025.
  • Business Quant data shows Cost of Revenue for CSTL at $18.3 million in Q4 2025, $18.7 million in Q3 2025, and $17.6 million in Q2 2025.